Lipocine Inc. Files 8-K Report
Ticker: LPCN · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, reporting, financials
Related Tickers: LPCN
TL;DR
Lipocine filed a standard 8-K on 9/30/25, no major news.
AI Summary
Lipocine Inc. filed an 8-K report on September 30, 2025, primarily to disclose other events and financial statements. The filing does not detail specific transactions or material events beyond routine reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Lipocine Inc. as of September 30, 2025, without immediate news of significant corporate actions.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any immediate material changes or risks.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- September 30, 2025 (date) — Date of Earliest Event Reported
- 675 Arapeen Drive, Suite 202 (address) — Principal executive offices
- Salt Lake City, Utah 84108 (address) — Principal executive offices
- 001-36357 (other) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Lipocine Inc.?
The primary purpose of this 8-K filing for Lipocine Inc. is to report 'Other Events' and 'Financial Statements and Exhibits' as of September 30, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is September 30, 2025.
What is Lipocine Inc.'s principal executive office address?
Lipocine Inc.'s principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
What is Lipocine Inc.'s Commission File Number?
Lipocine Inc.'s Commission File Number is 001-36357.
Does this filing indicate any former company name or address changes?
No, the filing explicitly states 'Not Applicable' for former company name or former address changes since the last report.
Filing Stats: 438 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2025-09-30 09:30:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 18KB
- form8-k_001.jpg (GRAPHIC) — 5KB
- ex99-1_002.jpg (GRAPHIC) — 5KB
- 0001493152-25-016210.txt ( ) — 246KB
- lpcn-20250930.xsd (EX-101.SCH) — 3KB
- lpcn-20250930_lab.xml (EX-101.LAB) — 33KB
- lpcn-20250930_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: September 30, 2025 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer